Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease

被引:3
|
作者
Baldaranov, Dobri [1 ]
Garcia, Victoria [1 ]
Miller, Garrett [1 ]
Donohue, Michael C. [1 ]
Shaw, Leslie M. [2 ]
Weiner, Mike [3 ,4 ,5 ,6 ,7 ]
Petersen, Ronald C. [8 ]
Aisen, Paul [1 ]
Raman, Rema [1 ]
Rafii, Michael S. [1 ]
机构
[1] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego 9860 Mesa Rim Rd, San Diego, CA 92121 USA
[2] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA
[3] Ctr Imaging Neurodegenerat Dis, Dept Vet Affairs Med Ctr, San Francisco, CA USA
[4] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Univ Calif San Francisco, Dept Psychiat & Behav Sci, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA
[8] Mayo Clin, Dept Neurol, Mayo Clin Study Aging, Mayo Clin Neurol & Neurosurg,Alzheimers Dis Res Ct, Rochester, MN USA
基金
美国国家卫生研究院;
关键词
adverse effects; Alzheimer's disease; biomarker; brain volume; cerebrospinal fluid; lumbar puncture; pain relief medication; MULTICENTER; BIOMARKERS;
D O I
10.1002/dad2.12431
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IntroductionLumbar puncture (LP) to collect and examine cerebrospinal fluid (CSF) is an important option for the evaluation of Alzheimer's disease (AD) biomarkers but it is not routinely performed due to its invasiveness and link to adverse effects (AE). MethodsWe include all participants who received at least one LP in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Study. For comparison between groups, two-sample t-tests for continuous, and Pearson's chi-square test for categorical variables were performed. ResultsTwo hundred twenty-seven LP-related AEs were reported by 172 participants after 1702 LPs (13.3%). The mean age of participants who reported at least one AE was 69.79 (standard deviation (SD) 6.3) versus none 72.44 (7.17) years (p < 0.001) with female predominance (115/172 = 67.4% vs 435/913 = 48%), and had greater entorhinal cortical thickness and hippocampal volume (3.903 (0.782) vs 3.684 (0.775) mm, p = 0.002; 7.38 (1.06) vs 7.05 (1.15) mm(3), p < 0.001), respectively. DiscussionWe found that younger age, female sex, and greater thickness of the entorhinal cortex were associated with a higher rate of LP-related AE reports.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Evaluation of the safety and tolerability of rivastygmine in patients with Alzheimer's disease dementia - Outcomes from the national EX-ON study
    Sobow, T
    Maczka, M
    Motyl, R
    Gabryelewicz, T
    Komorniczak, P
    Szczudlik, A
    Barcikowska, M
    Kloszewska, I
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 203 - 203
  • [32] Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome
    Carmona-Iragui, Maria
    Santos, Telma
    Videla, Sebastian
    Fernandez, Susana
    Benejam, Bessy
    Videla, Laura
    Alcolea, Daniel
    Blennow, Kaj
    Blesa, Rafael
    Lleo, Alberto
    Fortea, Juan
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 55 (04) : 1489 - 1496
  • [33] Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain
    Alcolea, Daniel
    Martinez-Lage, Pablo
    Izagirre, Andrea
    Clerigue, Montserrat
    Carmona-Iragui, Maria
    Alvarez, Rosa Maria
    Fortea, Juan
    Balasa, Mircea
    Morenas-Rodriguez, Estrella
    Llado, Albert
    Grau, Oriol
    Blennow, Kaj
    Lleo, Alberto
    Molinuevo, Jose L.
    JOURNAL OF ALZHEIMERS DISEASE, 2014, 39 (04) : 719 - 726
  • [34] Virtual reality device to improve the tolerability of lumbar puncture
    Hill, Katie
    Brown, Chris
    Gibbs, Austin
    Mitchell, Andrew Robert John
    BMJ NEUROLOGY OPEN, 2022, 4 (01)
  • [35] Memantine for the treatment of Alzheimer's disease: Tolerability and safety data from clinical trials
    Farlow M.R.
    Graham S.M.
    Alva G.
    Drug Safety, 2008, 31 (7) : 577 - 585
  • [36] Safety tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
    Sramek, JJ
    Anand, R
    Wardle, TS
    Irwin, P
    Hartman, RD
    Cutler, NR
    LIFE SCIENCES, 1996, 58 (15) : 1201 - 1207
  • [38] An investigation into the safety, tolerability, and efficacy of high dose rivastigmine treatment in Alzheimer's disease
    Shua-Haim, JR
    Pass, MD
    Patel, S
    Lee, P
    Patel, P
    NEUROBIOLOGY OF AGING, 2004, 25 : S196 - S196
  • [39] Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability
    Thussu, Shreeya
    Naidu, Aniketh
    Manivannan, Sindhu
    Grossberg, George T.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024, 24 (11) : 1045 - 1053
  • [40] Safety and tolerability of rivastigmine capsules plus memantine in patients with probable Alzheimer's disease
    Brannan, Stephen
    Koumaras, Barbara
    Figiel, Gary
    Farlow, Martin
    ANNALS OF NEUROLOGY, 2008, 64 : S40 - S41